Quelamycin: a summary of phase I clinical trials.
Quelamycin is triferric doxorubicin, a metallic derivative of adriamycin which, in experimental studies, has been found to have a better therapeutic index than adriamycin and no cardiotoxicity. In Spain, phase I clinical trials carried out in 96 patients with advanced cancer have shown that the drug has low toxicity and considerable antitumor activity, while it is not cardiotoxic, even at cumulative doses of nearly 3 g.
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005290:Ferric Compounds / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D005290:Ferric Compounds; C018376:quelamycin; D004317:Doxorubicin